Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Lupus: Treatment Update and Systemic Lupus Considerations
Description
The presentation focuses on recent advancements in the treatment of cutaneous lupus, emphasizing the importance of understanding the systemic implications of the condition. The speaker, a dermatologist and rheumatologist, discusses the rising incidence of cutaneous lupus leading to systemic lupus erythematosus (SLE), highlighting the need for dermatologists to be adept in screening for systemic disease while managing skin conditions. The discussion includes prevalence rates showing that skin manifestations are frequently indicative of systemic involvement, especially in cases of acute cutaneous lupus. The speaker reviews treatment options, indicating that antimalarials remain the first-line therapy due to their effectiveness and safety. Other treatments such as methotrexate, mycophenolate, and newer immunotherapies like anifrolumab are also discussed, showcasing a promising pipeline for future therapies. As new biologics emerge, there is a concerted effort to enhance treatment protocols based on systematic collaboration between dermatologists and rheumatologists, underscoring the significance of a comprehensive approach to patient care that considers both cutaneous and systemic aspects. Furthermore, the speaker notes the critical role of ongoing monitoring and adapting treatment strategies based on individual patient responses.
View moreConclusions
- Cutaneous lupus can present with both skin and systemic manifestations, highlighting the need for careful evaluation for systemic lupus erythematosus (SLE) in patients with cutaneous lupus.
- Patients with acute cutaneous lupus have a very high likelihood of having associated systemic disease, while discoid lupus shows varied risks depending on its extent.
- Monitoring strategies for cutaneous lupus should include assessing for SLE and periodic lab testing to catch potential systemic involvement early.
- New treatment options for cutaneous lupus are emerging, including targeted biologics like anifrolumab and deucravacitinib, which show promising results in managing skin symptoms associated with SLE.
- Antimalarials remain the first-line treatment for skin lupus, with methotrexate and mycophenolate being important secondary options.
- Drug-induced cutaneous lupus should be considered, especially with commonly used medications such as antihypertensives and proton pump inhibitors.
- Recent advances in therapeutic strategies for skin lupus include potential combination therapies with established treatments for systemic lupus.
- Co-management between dermatology and rheumatology is critical for optimizing treatment outcomes in patients with both skin and systemic lupus.
- Emerging classification criteria and core outcome measures are improving the understanding and management of cutaneous lupus.
- Overall, the field of cutaneous lupus is advancing, with new therapeutic options and strategies in development to better address the complex needs of affected patients.
- Watanabe T, et al. Dermatology. 1995;190(4):277-283.
- Klein RS, et al. Rheum Dis Clin North Am. 2010;36(1):33-51, vii.
- Vera-Recabarren MA, et al. Br J Dermatol. 2010;162(1):91-101.
- Biazar C, et al. Autoimmun Rev. 2013;12(3):444-454.
- Elman SA, ..., Merola JF. Clin Exp Dermatol. 2020;45(1):89-91.
- Marzano AV, et al. Lupus. 2009;18(11):935-940.
- Lowe GC, et al. Br J Dermatol. 2011;164(3):465-472.
- Cabanillas M, et al. Dermatol Online J. 2012 Aug;18(8):12.
- Gladman DD, et al. J Rheumatol. 2013;40(5):630-633.
- Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
- British Association of Dermatologists. Br J Dermatol, Volume: 185, Issue: 6, Pages: 1112-1123, First published: 25 June 2021, DOI: 10.1111/bjd.20597.
- Cortes-Hernandez J, et al. Br J Dermatol 2012; 166 (3): 616-623.
- Cortés-Hernández et al. Arthritis Research & Therapy 2012, 14:R265.
- Manzi et al, Ann Rheum Dis 71:1833, 2012.
- Guo LN, et al. Lupus Science & Medicine 2021;8:e000529. doi:10.1136/lupus-2021-000529.
- Merola JF, et al. Lupus Sci Med. 2021 Mar;8(1) PMID: 33658303.